First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Daiichi Sankyo
Related studies linked through entity extraction aliases.
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation
- Status
- COMPLETED
- Phase
- N/A
TRUDI: TDXD+Durva in HER2+/Low IBC
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- N/A
A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
- Status
- RECRUITING
- Phase
- N/A
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
- Status
- COMPLETED
- Phase
- PHASE2
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Dose Finding Study of VN-0200
- Status
- COMPLETED
- Phase
- PHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Status
- RECRUITING
- Phase
- PHASE2